NCT04027946 2024-04-16LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)National Institutes of Health Clinical Center (CC)Phase 2 Terminated6 enrolled 14 charts